Ann Driessen © ECCO

Pamela Baldin © ECCO

The animal model is a useful tool to unravel different pathogenetic mechanisms, to detect biomarkers for monitoring and to test the efficacy and safety of drugs in the preclinical phase. In Inflammatory Bowel Disease (IBD) research, the mouse is the most widely used animal model. Animal models are classified into four categories, namely chemical models, cell transfer models, genetically engineered models, and congenic models. Based on the mechanism of the animal model, different aspects of the pathogenesis of intestinal inflammation in IBD are examined, such as epithelial integrity and wound healing, and innate and adaptive immunity [1].

Note: Due to the COVID-19 pandemic, the 14^th European Colorectal Congress will be virtual. The article below was submitted prior to this decision. Please refer to the ECC Congress website to check on the latest update.

Michel Adamina © ECCO

The 14^th European Colorectal Congress opens on Sunday, November 29, 2020 with a Masterclass in Colorectal Surgery and a Course in Proctology, followed by three days of expert lectures until the Congress closes on Wednesday, December 2, 2020. A carefully devised safety approach overseen by the Swiss health authorities is allowing the organisation of this large European meeting, traditionally attended by more than 1000 participants from 80 countries who travel to the St.Gallen Colorectal Week (www.colorectalsurgery.eu, @ECCongress). Michel Adamina, from S-ECCO, is co-organising the meeting.

Marjo Campmans-Kuijpers  © ECCO

During the recent COVID-19 outbreak, telemedicine was helpful in ensuring the continuation of regular care and reducing the need for outpatient visits. To optimise the treatment of Inflammatory Bowel Disease (IBD), recent guidelines recommend strict long-term monitoring of the mucosal inflammation and timely optimisation of treatment during a disease flare [1]. In traditional practice, such monitoring requires many visits to outpatient clinics by patients, which they can experience as stressful. This regular monitoring increases the workload and administration during outpatient visits and can lead to longer waiting lists. In order to address some of these issues and continue to provide patients with good and qualitatively safe care, the multidisciplinary team (MDT) together with the Dutch patient association (CCUVN) developed the telemonitoring tool MyIBDCoach. In the Netherlands, there are currently about 90,000 patients with IBD [2] and 10% of these patients are using MyIBDCoach.

Susanna Jäghult © ECCO

Wladzia Czuber-Dochan © ECCO

We know that all nurses constantly strive to enhance the standard of patient care, and this is also true for IBD services. The best way for nurses to improve patient care is by developing their knowledge and skills and applying them in clinical practice. Many nurses are actively involved in research and practice innovation projects that aim to improve patient care and quality of life. We believe that it is important to share with all nurses the information gained from such projects. The new discoveries made in your own practice may also be beneficial for colleagues and patients in other countries. N-ECCO offers a great opportunity for you to share your work with others, and we would like to invite you to tell us about the important work that you are doing in your clinic.

Antonino Spinelli  © ECCO

The ECCO Guidelines Committee (GuiCom) is known to be one of the busiest committees in the busy ECCO! 2020 has definitely been quite a challenging year so far, but no crisis will prevent us from introducing our newest Committee Member, Hannah Gordon.

Henit Yanai  © ECCO

The European Crohn’s and Colitis Organisation (ECCO) brings together national groups and individuals interested in different aspects of Inflammatory Bowel Diseases (IBD). One of ECCO’s core aims is to promote education in the field of IBD and thereby improve the quality of care for IBD patients throughout Europe.

Sophie Restellini © ECCO

Valerie Pittet © ECCO

Introduction

Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), leading to coronavirus disease 2019 (COVID-19), spread exponentially, with the World Health Organization (WHO) declaring a pandemic on March 11 [1]. By August 15, more than 21,000,000 cases and 755,000 deaths had been reported worldwide [2]. People of any age with certain underlying medical conditions are at increased risk for severe illness from COVID-19.

Call for proposal of rare cases now open!

ECCO COllaborative Network For Exceptionally Rare Case Reports (CONFER) is an initiative to identify, assemble and report together rare IBD cases of clinical relevance, which are otherwise seldom reported. By joining forces with the many Members and supporters of ECCO, a joint report of all similar rare cases can result in a large case series that will advance our knowledge about these uncommon patients.

Take your study to the next level with the IBD National Study Group Meeting at the ECCO Congress

Shaji Sebastian  © ECCO

One of the missions of the Clinical Research Committee of ECCO (ClinCom) is to facilitate innovative clinical research in the area of Inflammatory Bowel Diseases (IBD).

To promote international scientific collaboration among researchers from different European countries, ClinCom established the IBD National Study Group Meeting, which takes place at the annual ECCO Congress. With this great platform, ClinCom enables investigators to have their studies challenged and promoted at the same time. Before the meeting, investigators are invited to provide a study synopsis for their project, including background, design, objectives, outcome parameters, major inclusion and exclusion criteria, statistics and co-variates. Submitted projects are then reviewed by ClinCom and, if found feasible, discussed during the IBD National Study Group Meeting at the ECCO Congress.

Arshdeep Singh © Arshdeep Singh

ECCO-AOCC Travel Grant Awardee

I accepted the ECCO AOCC Travel Grant 2020 with great pleasure and in all humility. The grant enabled me to visit Helsinki University Central Hospital in Finland between January 13 and March 6, 2020. This gave me the opportunity to increase my knowledge on the management of IBD patients and to gain insight into the faecal microbiota transplant and human microbiome research programme in Finland. At the Hospital District of Helsinki and Uusimaa (HUS), I attended the IBD clinics and IBD inpatient rounds, which greatly enriched my experience. Further, I learned more about IBD endoscopy, including double-balloon enteroscopy and capsule endoscopy for Crohn’s Disease and faecal microbiota transplant (FMT). I intend to deploy this knowledge at our IBD centre to foster further professional growth.